Frontlight ResearchEarly access
Active, not recruitingPhase 4
Dupixent Study for Alternate Administration
Key facts
- Who runs it
- Madigan Army Medical Center
- Where
- Tacoma, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 4
- People taking part
- 30 people, planned
- Started
- 14 Oct 2021
- Ended
- Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dupilumab
- Record updated
- 17 January 2025
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age=>18 y/o with recurrent CRSwNP based on reported symptoms and endoscopic assessment
- history of atleast 1 endoscopic sinus surgery
- Current use of intranasal corticosteroid spray or irrigation
- Active duty servicemembers must be in the area for at least 7 months after starting the medication to complete the necessary follow ups
Who cannot take part
- Previous use of other biologic therapy in last 6 months
- if history of asthma, FEV1< 50%
- history of cystic fibrosis, eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, kartagener syndrome, primary ciliary dyskinesia
- Patient is a pregnant woman, may become pregnant or breastfeeding
Other criteria
- Eligibility: patients =>18 years old with recurrent chronic rhinosinusitis with nasal polyposis (CRSwNP) despite standard of care (i.e topical medical therapies and full endoscopic sinus surgery)
Where in United States
- Madigan Army Medical CenterTacoma, United States
About the trial
What the trial wants to find out
Investigators will investigate an alternate Dupilumab administration schedule in patients with recurrent chronic rhinosinusitis with nasal polyposis, who have a history of full endoscopic sinus surgery and are on appropriate topical medical therapies. Specifically, investigators will investigate if the alternate schedule of drug administration is non-inferior in both subjective and objective outcomes.
The 2 groups in the trial
- Arm A - Regular AdminstrationExisting treatment, for comparison
Eligible patient will receive 300 mg Subcutaneous Dupilumab every 2 weeks for 28 weeks
Treatment: Dupilumab
- Arm B - Alternate AdministrationTreatment being tested
Eligible patient will receive 300 mg Subcutaneous Dupilumab every 2 weeks for 8 weeks and then every 4 weeks up until 28 weeks
Treatment: Dupilumab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Alternate Dupilumab Schedule in Recurrent Chronic Rhinosinusitis With Nasal Polyposis Patients
- Record updated
- 17 January 2025